{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:41:20Z","timestamp":1761896480679},"reference-count":35,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T00:00:00Z","timestamp":1488758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Diabetes Invest"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims\/Introduction<\/jats:title><jats:p>Although sodium\u2010glucose cotransporter 2 inhibitors are a promising treatment for type 2 diabetes mellitus, they are associated with concerns about specific adverse drug reactions. We carried out a 1\u2010year post\u2010marketing study of tofogliflozin, a novel agent in this class, in Japanese elderly patients with type 2 diabetes mellitus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>This was a prospective, observational and multicenter post\u2010marketing study carried out in the context of routine clinical practice. The study included all type 2 diabetes patients aged \u226565 years who started treatment with tofogliflozin during the first 3 months after its launch on 23 May 2014.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 1,535 patients registered, 1,507 patients whose electronic case report forms were collected and who had at least one follow\u2010up visit were included in the safety analysis. A total of 270 of 1,507 patients (17.92%) had at least one adverse drug reaction to tofogliflozin. The incidences of adverse drug reactions of special interest, namely, polyuria\/pollakiuria, volume depletion\u2010related events, urinary tract infection, genital infection, hypoglycemia and skin disorders were 2.92, 3.85, 2.06, 1.33, 1.06 and 2.39%, respectively. Among those patients evaluable for clinical effectiveness, the mean change in glycated hemoglobin and bodyweight from baseline to last visit was \u22120.46% (<jats:italic>P<\/jats:italic> &lt; 0.0001) and \u22122.71 kg (<jats:italic>P<\/jats:italic> &lt; 0.0001), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The present study showed that the incidence of adverse drug reactions to tofogliflozin in this study of elderly patients aged \u226565 years differed little from the incidence in the preapproval clinical trials. It was shown that tofogliflozin significantly decreased glycated hemoglobin levels.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdi.12626","type":"journal-article","created":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T23:23:15Z","timestamp":1484954595000},"page":"766-775","source":"Crossref","is-referenced-by-count":25,"title":["Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post\u2010marketing study (J\u2010<scp>STEP<\/scp>\/<scp>EL<\/scp> Study)"],"prefix":"10.1111","volume":"8","author":[{"given":"Kazunori","family":"Utsunomiya","sequence":"first","affiliation":[{"name":"Division of Diabetes, Metabolism and Endocrinology Department of Internal Medicine Jikei University School of Medicine Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Shimmoto","sequence":"additional","affiliation":[{"name":"Post Marketing Surveillance Department Kowa Company, Ltd. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Senda","sequence":"additional","affiliation":[{"name":"Medical Affairs Sanofi K.K. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Kurihara","sequence":"additional","affiliation":[{"name":"Post Marketing Surveillance Department Kowa Company, Ltd. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoji","family":"Gunji","sequence":"additional","affiliation":[{"name":"Post Marketing Surveillance Department Kowa Company, Ltd. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Fujii","sequence":"additional","affiliation":[{"name":"Post Marketing Surveillance Department Kowa Company, Ltd. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seigo","family":"Kakiuchi","sequence":"additional","affiliation":[{"name":"Post Marketing Surveillance Department Kowa Company, Ltd. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisataka","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Post Marketing Surveillance Department Kowa Company, Ltd. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kameda","sequence":"additional","affiliation":[{"name":"Medical Affairs Sanofi K.K. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tamura","sequence":"additional","affiliation":[{"name":"Diabetes &amp; Cardiovascular Medical Operations Sanofi K.K. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Kaku","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine 1 Kawasaki Medical School Kurashiki Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)61032-X"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60207-9"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01512.x"},{"key":"e_1_2_7_5_1","unstructured":"BolenS TsengE HutflessS et al.Diabetes Medications for Adults With Type 2 Diabetes: An Update. Comparative Effectiveness Reviews No. 173. Agency for Healthcare Research and Quality 2016."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12214"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2012.12.004"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01511.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.512"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm300884k"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.191593"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2014.50.11.2232267"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.916278"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0229-1"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-13-65"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12538"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.887680"},{"key":"e_1_2_7_18_1","unstructured":"Kowa Company Ltd.Package insert for Deberza 20 mg Tablet (in Japanese). Available from:http:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/270072_3969021F1032_1_06#CONTRAINDICATIONS. Accessed October 3 2016."},{"key":"e_1_2_7_19_1","unstructured":"Sanofi KK Package insert for Apleway 20 mg Tablet (in Japanese). Available from:http:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/780069_3969021F1024_1_06# CONTRAINDICATIONS. Accessed October 3 2016."},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2016.02.003"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1034105"},{"key":"e_1_2_7_22_1","unstructured":"Kowa Company Ltd.Risk management plan for Deberza 20 mg Tablet. December 2015 (in Japanese). Available from:http:\/\/www.pmda.go.jp\/files\/000209090.pdf. Accessed October 3 2016."},{"key":"e_1_2_7_23_1","unstructured":"SanofiKK.Risk management plan for Apleway 20 mg Tablet. December 2015 (in Japanese). Available from:http:\/\/www.pmda.go.jp\/files\/000209091.pdf. Accessed October 3 2016."},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12513"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2328w"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-014-0031-5"},{"key":"e_1_2_7_27_1","unstructured":"Ministry of Health Labour and Welfare Japan.Summary of Patient Survey 2011. Available from:http:\/\/www.mhlw.go.jp\/english\/database\/db-hss\/sps_2011.html. Accessed October 3 2016."},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-013-0039-6"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-016-0163-1"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2014.40"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.12.052"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1380"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP151126.CS"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12401"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0264-4"}],"container-title":["Journal of Diabetes Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdi.12626","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.12626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:08:50Z","timestamp":1695550130000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdi.12626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1111\/jdi.12626"],"URL":"https:\/\/doi.org\/10.1111\/jdi.12626","archive":["Portico"],"relation":{},"ISSN":["2040-1116","2040-1124"],"issn-type":[{"value":"2040-1116","type":"print"},{"value":"2040-1124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,6]]}}}